Global Huntington’s Disease Treatment Market Forecast Report by Drug Type (Approved Drugs, Off-label Drugs) End user (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Pharmacy) Countries and Company Analysis, 2024-2032

Growing Number of Instances of the Illness to Encourage Market Growth:

One of the main drivers of market expansion is the rising prevalence of this illness around the world, especially in the United States and the major European nations. Although there is no known treatment for this inherited neurodegenerative illness, its symptoms are manageable. It mostly affects limb and face muscles and is characterized by uncontrollable twitching motions known as chorea that get worse with time.

In 2023, a post on Rare Disease Advisor stated that the estimated prevalence of Huntington's disease (HD) was 8.87 per 100,000 in North America and 6.37 per 100,000 in Europe. The need for more potent treatment interventions to regulate and manage related symptoms is anticipated to rise in light of the disease's rising incidence in developing nations like Africa, China, and India.

Growing Government Efforts to Increase Market Growth by Raising Awareness of Huntington's Disease Treatment:

Globally, governments are introducing fresh initiatives, public awareness campaigns, and support networks to enlighten people about this illness. This will eventually result in an increase in the number of cases being identified and a surge in the need for cutting-edge treatment choices.

The HD Human Biology Project under the HDSA received USD 898,194 to support six new initiatives with the purpose of understanding and finding new effective treatment approaches for Huntington's disease, according to the Huntington's Disease Society of America (HDSA) 2023 booklet.

In addition, the growing number of government awareness campaigns aimed at educating the public about the illness and potential treatments will help to drive market expansion.

For example, the Huntington's Society of Canada held events like the HD Hockey Classic and the Huntington Heroes National Virtual Walk during May 2022 to raise awareness of Huntington Disease (HD) and to foster a sense of community and optimism.

North America Huntington’s Disease Treatment Market

Because of the growing prevalence of Huntington's disease, the existence of major players, and the government's increasing investment for research and development, North America is anticipated to hold a sizable market share during the projection period. Approximately 30,000 Americans are afflicted with Huntington's disease each year, according to data released by Cleveland Clinic in January 2021. The study also stated that there were 5.7 cases of the disease per 100,000 persons in North America per year. The demand for effective treatments is expected to increase as Huntington's disease becomes more common in this area, propelling the target market's growth over the course of the forecast period.

Over the course of the forecast period, players' increasing R&D and product development efforts are anticipated to drive the market's expansion. For example, PTC Therapeutics initiated a Phase 2 trial in the United States in April 2022 to assess PTC518, an experimental therapy for Huntington's disease. The two-part PIVOT-HD experiment will be carried out at clinical institutions across the globe. Participants will be randomly randomized to receive either PTC518 (roughly three months) or a placebo before being observed for 12 weeks. This first section will assess PTC518's pharmacology and pharmacodynamic effect—that is, the interactions between the body and a certain molecule.  In the second phase, PTC518 will be administered, and researchers will monitor the effects on disease biomarkers for nine months. The Food and Drug Administration (FDA) granted Sage Therapeutics Inc. fast-track designation for SAGE-718, a prospective HD treatment, in September 2021. With the goal of delaying the advancement of Huntington's disease, Galyan Bio intended to start a clinical trial for its small molecules candidate in June 2021 in association with Bicoll GmbH.

Global Huntington’s Disease Treatment Company Analysis:

Some leading Huntington’s Disease Treatment companies are H Lundbeck, Pfizer Inc., Bausch Health Cos, Teva Pharmaceutical Industries, Dr Reddy's Laboratories, Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals Plc, Alnylam Pharmaceuticals, Novartis AG, UniQure.

Global Huntington’s Disease Treatment Company News:

October 2023: The US Food and medication Administration (FDA) designated Sage Therapeutics' SAGE-718 as an orphan medication for the treatment of Huntington's disease.

September 2023: The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences, Inc.'s New Drug Application (NDA) for INGREZZA (valbenazine) oral granules, a novel sprinkle formulation.

August 2023: The US Food and Drug Administration (FDA) approved valbenazine, which is sold under the brand name INGREZZA, to treat these symptoms. The company Neurocrine Biosciences is the drug's developer.

April 2023: At the American Academy of Neurology (AAN) Annual Meeting, Prilenia Therapeutics B.V. presented the top-line results from the Phase 3 PROOF-HD clinical study, which looked at the efficacy and safety of pridopidine in people with Huntington's disease (HD).

Drug Type –Market Breakup in 2 Viewpoints

1. Approved Drugs
2. Off-label Drugs

End Users – Market Breakup in 3 Viewpoints

1. Hospital Pharmacy
2. Drug Store & Retail Pharmacy
3. Online Pharmacy

Geography – Market Breakup of 23 countries

North America

•    United States
•    Canada

Europe

•    France
•    Germany
•    Italy
•    Spain
•    United Kingdom
•    Belgium
•    Netherland
•    Turkey

Asia Pacific

•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Thailand
•    Malaysia
•    Indonesia
•    New Zealand

Latin America

•    Brazil
•    Mexico
•    Argentina

Middle East & Africa

•    South Africa
•    Saudi Arabia
•    UAE

Rest of the World
 

Company Insights:

•    Overview
•    Recent Development
•    Product Portfolio
•    Revenue

Key Players Analysis:

1. H Lundbeck
2. Pfizer Inc.
3. Bausch Health Cos
4. Teva Pharmaceutical Industries
5. Dr Reddy's Laboratories
6. Sun Pharmaceutical Industries Limited 
7. Hikma Pharmaceuticals Plc
8. Alnylam Pharmaceuticals
9. Novartis AG
10. UniQure

Report Details: